On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKMﾙ-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection.

iBio planned to continue working with the Infectious Disease Research Institute in Seattle and the Texas A&M University System, and expected to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.